Namir Hassan
Company: Zelluna Immunotherapy
Job title: CEO
Seminars:
Chair’s Opening Remarks 9:55 am
day: Day One
Keynote Panel Discussion – Driving Clinical Success in Solid Tumor Settings 10:00 am
What is the optimal cell type to tackle the solid tumor microenvironment What solid tumors should the field be targeting first, considering myeloid compartments and heterogeneity? Address acquired versus inherent resistance to immunotherapy Discuss how different modalities induce epitope spreading and the potential of this to overcome heterogeneityRead more
day: Day One